Spyre Therapeutics Inc
For the period ended Dec 31, 2023. Filed Feb 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 29, 2024
SYRE$103.86+7.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $188,893 | $34,863 |
| Marketable securities | 150,384 | 20,848 |
| Development receivables | — | 375 |
| Prepaid expenses and other current assets | 2,251 | 6,172 |
| Total current assets | 341,528 | 62,258 |
| Restricted cash | 322 | 1,553 |
| Property and equipment, net | — | 3,220 |
| Operating lease right-of-use assets | — | 3,430 |
| Other non-current assets | 9 | 683 |
| TOTAL ASSETS | $341,859 | $71,144 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $896 | $677 |
| CVR liability | 1,390 | — |
| Operating lease liabilities | — | 625 |
| Deferred revenue | — | 517 |
| Accrued and other current liabilities | 13,108 | 12,837 |
| Related party accounts payable and other current liabilities | 16,584 | — |
| Total current liabilities | 31,978 | 14,656 |
| Non-current CVR liability | 41,310 | — |
| Non-current operating lease liabilities | — | 4,004 |
| Deferred revenue, net of current portion | — | 2,179 |
| TOTAL LIABILITIES | 73,288 | 20,839 |
| Commitments and Contingencies (Note 9) | ||
| Series B non-voting convertible preferred stock, $0.0001 par value; 150,000 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 150,000 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. | 84,555 | — |
| STOCKHOLDERS’ EQUITY | ||
| Series A non-voting convertible preferred stock, $0.0001 par value; 1,086,341 and no shares authorized as of December 31, 2023 and December 31, 2022, respectively; 437,037 and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. | 184,927 | — |
| Preferred stock, $0.0001 par value; 8,763,659 shares and 10,000,000 authorized as of December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding as of December 31, 2023 and December 31, 2022. | — | — |
| Common stock, $0.0001 par value; 400,000,000 and 20,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 36,057,109 shares and 2,614,014 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. | 10 | 6 |
| Additional paid-in capital | 763,191 | 475,971 |
| Accumulated other comprehensive income (loss) | 302 | (48) |
| Accumulated deficit | (764,414) | (425,624) |
| TOTAL STOCKHOLDERS’ EQUITY | 184,016 | 50,305 |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY | $341,859 | $71,144 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.